Cytek Biosciences, Inc. CTKB
5.65
(0.08)
(1.40%)
as of 25 Sep
- Market cap
- $744.8M
- P/E
- 0.0×
Follow CTKB
Growth Flags
show if company had growth for consecutive years
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 36.38 | 36.38 | 5,100.00 | 541.18 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | 6.05 | 6.05 | 9.79 | 8.30 | 6.22 | 4.23 | 3.20 |
P/FCF ratio |
— | 63.51 | 63.51 | 4,708.38 | 0.00 | 3,208.45 | 38.64 | 0.00 |
P/Operating CF |
— | (152.80) | (152.80) | 229.89 | 219.80 | 126.15 | 424.47 | (836.73) |
P/B ratio |
— | 0.00 | 0.00 | 3.09 | 3.20 | 3.05 | 2.14 | 1.89 |
Price to Tangible BV |
— | 0.00 | 0.00 | 3.21 | 3.31 | 3.39 | 2.36 | 2.09 |
EV/Sales |
— | 4.43 | 4.43 | 6.94 | 6.21 | 4.86 | 2.85 | 1.91 |
EV/EBITDA |
— | 36.57 | 36.57 | 85.37 | 264.46 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | 36.97 | 36.97 | 191.75 | (83.35) | 177.78 | 22.49 | (81.97) |
EV/FCF |
— | 46.54 | 46.54 | 3,337.63 | (46.38) | 2,510.34 | 26.02 | (44.54) |
Quick Ratio |
— | 2.28 | 6.90 | 11.89 | 8.01 | 5.67 | 5.00 | 4.16 |
Current Ratio |
— | 3.22 | 7.86 | 13.01 | 9.26 | 6.97 | 5.86 | 5.04 |
Net Debt/EBITDA |
— | (9.84) | (11.65) | (35.06) | (88.66) | 14.03 | 27.59 | 9.19 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.44% | 0.33% | 0.21% | 0.11% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 1.63 | 0.64 | 0.37 | 0.33 | 0.38 | 0.40 | 0.42 |
Operating CF/Net income |
— | 0.82 | 4.71 | 0.00 | (4.75) | (0.43) | (4.22) | 0.07 |
Capex/Depreciation |
— | 0.00 | (2.57) | (3.51) | (1.74) | (0.52) | (0.33) | (0.33) |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 58.30% | (11.14%) | 0.00% | 0.62% | (2.97%) | (1.53%) | (18.05%) | |
| — | (47.41%) | 2.21% | 0.00% | 0.52% | (2.40%) | (1.21%) | (13.85%) | |
ROIC |
— | 0.00% | 70.14% | 14.04% | (1.35%) | (13.19%) | (10.79%) | (31.26%) |
Return on Tangible Assets |
— | (35.23%) | 1.75% | 0.00% | 0.62% | (3.43%) | (1.74%) | (20.03%) |
Average Days of Receivables |
— | 111.90 | 66.80 | 84.90 | 108.73 | 105.76 | 110.32 | 113.23 |
Research and Development Expense of Revenue |
— | 15.43% | 14.75% | 19.10% | 21.25% | 22.87% | 19.66% | 18.10% |
Selling, General and Administrative Expense of Revenue |
— | 29.34% | 26.24% | 35.60% | 41.41% | 48.24% | 46.01% | 53.79% |
Intangible Assets out of Total Assets |
0.00 | 0.01 | 0.00 | 0.03 | 0.03 | 0.08 | 0.07 | 0.07 |
Share Based Compensation of Revenue |
— | 0.00% | 0.66% | 5.15% | 10.12% | 11.42% | 13.39% | 12.20% |
Graham Net Nets |
— | 0.28 | 0.28 | 0.30 | 0.26 | 0.24 | 0.35 | 0.42 |
Graham Number |
— | 0.00 | 0.00 | 0.62 | 1.15 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | 2.75% | 2.75% | 0.02% | 0.18% | (1.01%) | (0.81%) | (10.10%) |
Free Cash Flow Yield |
— | 1.57% | 1.57% | 0.02% | (1.61%) | 0.03% | 2.59% | (1.34%) |
Revenue per Share |
— | 0.44 | 3.19 | 1.67 | 1.22 | 1.43 | 1.53 | 1.58 |
Operating CF per Share |
— | (0.10) | 0.52 | 0.06 | (0.09) | 0.04 | 0.19 | (0.04) |
Capex per Share |
— | 0.00 | (0.05) | (0.06) | (0.07) | (0.04) | (0.03) | (0.03) |
Free Cash Flow per Share |
— | (0.10) | 0.47 | 0.00 | (0.16) | 0.00 | 0.17 | (0.07) |
Cash per Share |
— | 0.23 | 5.70 | 4.75 | 2.56 | 1.94 | 2.13 | 2.05 |
Shareholders Equity per Share |
— | 0.25 | 6.12 | 5.28 | 3.16 | 2.91 | 3.03 | 2.68 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.25 | 6.12 | 5.28 | 3.16 | 2.91 | 3.03 | 2.68 |
Free Cash Flow |
— | (13.75) | 13.61 | 0.27 | (22.10) | 0.45 | 21.94 | (8.62) |
Working Capital |
— | 46.73 | 182.09 | 398.55 | 404.98 | 335.83 | 328.78 | 314.19 |
Capital Expenditures |
— | (0.97) | (1.55) | (4.36) | (9.87) | (4.83) | (3.44) | (3.94) |
Net Current Asset Value |
— | 29.73 | 166.93 | 373.81 | 360.09 | 290.67 | 292.68 | 272.19 |
EV/EBIT |
— | 38.32 | 38.32 | 96.95 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | 0.02 | 0.03 | 0.06 | 0.03 | 0.02 | 0.02 |
Net Profit Margin |
— | (29.07%) | 3.46% | 0.00% | 1.57% | (6.29%) | (3.00%) | (33.02%) |
Price to Operating Income |
— | 52.30 | 52.30 | 136.77 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.30 | 0.28 | 0.21 | 0.41 | 0.50 | 0.58 | 0.66 |
Cash ROIC |
— | (23.40%) | 3.78% | (0.16%) | (3.36%) | (2.00%) | 1.10% | (3.76%) |
Accounts Receivable Turnover |
— | 3.23 | 5.35 | 5.47 | 4.17 | 3.68 | 3.44 | 3.27 |
Accounts Payable Turnover |
— | 11.05 | 15.56 | 16.33 | 16.09 | 21.33 | 20.87 | 16.25 |
Inventory Turnover |
— | 1.41 | 1.98 | 1.77 | 1.57 | 1.53 | 1.71 | 2.10 |
Average Days of Payables |
— | 29.27 | 26.13 | 22.69 | 27.81 | 13.24 | 22.59 | 24.11 |
Days of Inventory on Hand |
— | 230.35 | 204.27 | 240.59 | 278.71 | 265.83 | 179.31 | 182.17 |
Average Receivables |
— | 17.93 | 17.37 | 23.38 | 39.31 | 52.40 | 58.26 | 61.55 |
Average Payables |
— | 2.64 | 2.64 | 2.99 | 3.92 | 3.92 | 4.28 | 5.97 |
Average Inventory |
— | 20.73 | 20.73 | 27.59 | 40.16 | 54.52 | 52.39 | 46.16 |
Average Assets |
— | 35.50 | 145.48 | 341.64 | 491.39 | 506.97 | 496.98 | 480.52 |
Average Common Equity |
— | (28.86) | (28.86) | 194.68 | 415.47 | 409.31 | 394.40 | 368.74 |
Columns are period end dates